DNA priming and influenza vaccine immunogenicity: Two phase 1 open label randomised clinical trials

The Lancet Infectious Diseases

Volumn 11, Issue 12, 2011, Pages 916-924

  Ledgerwood, Julie E ^a   Wei, Chih Jen ^a   Hu, Zonghui ^a   Gordon, Ingelise J ^a   Enama, Mary E ^a   Hendel, Cynthia S ^a   McTamney, Patrick M ^a   Pearce, Melissa B ^b   Yassine, Hadi M ^a   Boyington, Jeffrey C ^a   Bailer, Robert ^a   Tumpey, Terrence M ^b   Koup, Richard A ^a   Mascola, John R ^a   Nabel, Gary J ^a   Graham, Barney S ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE; NEUTRALIZING ANTIBODY;

ADULT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HEMAGGLUTINATION INHIBITION; HUMAN; IMMUNOGENICITY; INFLUENZA VACCINATION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADOLESCENT; ADULT; ANTIBODIES, VIRAL; CYTOKINES; HUMANS; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MIDDLE AGED; VACCINES, DNA; VACCINES, INACTIVATED; YOUNG ADULT;

EID: 81855182191     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(11)70240-7     Document Type: Article

References (36)

1. WHO Influenza (seasonal) fact sheet 2009, World Health Organization, Geneva, Switzerland.
2. Luke C, Subbarao K Vaccines for pandemic influenza. Emerg Infect Dis 2006, 12:66-72.
3. Bastien N, Antonishyn NA, Brandt K, et al. Human infection with a triple-reassortant swine influenza A(H1N1) virus containing the hemagglutinin and neuraminidase genes of seasonal influenza virus. J Infect Dis 2010, 201:1178-1182.
4. Garten RJ, Davis CT, Russell CA, et al. Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans. Science 2009, 325:197-201.
5. Shinde V, Bridges CB, Uyeki TM, et al. Triple-reassortant swine influenza A (H1) in humans in the United States, 2005-2009. N Engl J Med 2009, 360:2616-2625.
6. Belshe RB The origins of pandemic influenza-lessons from the 1918 virus. N Engl J Med 2005, 353:2209-2211.
7. WHO Confirmed human cases of avian influenza A(H5N1) (accessed Aug 14, 2011). http://www.who.int/csr/disease/avian_influenza/country/cases_table_2011_06_16/en/index.html.
8. Whittle JR, Zhang R, Khurana S, et al. Broadly neutralizing human antibody that recognizes the receptor-binding pocket of influenza virus hemagglutinin. Proc Natl Acad Sci USA 2011, 108:14216-14221.
9. Knossow M, Skehel JJ Variation and infectivity neutralization in influenza. Immunology 2006, 119:1-7.
10. Potter CW, Oxford JS Determinants of immunity to influenza infection in man. Br Med Bull 1979, 35:69-75.
11. Ekiert DC, Bhabha G, Elsliger MA, et al. Antibody recognition of a highly conserved influenza virus epitope. Science 2009, 324:246-251.
12. Sui J, Hwang WC, Perez S, et al. Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat Struct Mol Biol 2009, 16:265-273.
13. Okuno Y, Isegawa Y, Sasao F, Ueda S A common neutralizing epitope conserved between the hemagglutinins of influenza A virus H1 and H2 strains. J Virol 1993, 67:2552-2558.
14. Corti D, Suguitan AL, Pinna D, et al. Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine. J Clin Invest 2010, 120:1663-1673.
15. Kashyap AK, Steel J, Oner AF, et al. Combinatorial antibody libraries from survivors of the Turkish H5N1 avian influenza outbreak reveal virus neutralization strategies. Proc Natl Acad Sci USA 2008, 105:5986-5991.
16. Wei CJ, Boyington JC, McTamney PM, et al. Induction of broadly neutralizing H1N1 influenza antibodies by vaccination. Science 2010, 329:1060-1064.
17. Graham BS, Koup RA, Roederer M, et al. Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine. J Infect Dis 2006, 194:1650-1660.
18. Martin JE, Sullivan NJ, Enama ME, et al. A DNA vaccine for Ebola virus is safe and immunogenic in a phase I clinical trial. Clin Vaccine Immunol 2006, 13:1267-1277.
19. Treanor JJ, Campbell JD, Zangwill KM, Rowe T, Wolff M Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N Engl J Med 2006, 354:1343-1351.
20. Wei C-J, Boyington JC, Dai K, et al. Cross-neutralization of 1918 and 2009 influenza viruses: role of glycans in viral evolution and vaccine design. Sci Transl Med 2010, 2:24ra1.
21. Stephenson I, Wood JM, Nicholson KG, Charlett A, Zambon MC Detection of anti-H5 responses in human sera by HI using horse erythrocytes following MF59-adjuvanted influenza A/Duck/Singapore/97 vaccine. Virus Res 2004, 103:91-95.
22. Catanzaro AT, Koup RA, Roederer M, et al. Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector. J Infect Dis 2006, 194:1638-1649.
23. Catanzaro AT, Roederer M, Koup RA, et al. Phase I clinical evaluation of a six-plasmid multiclade HIV-1 DNA candidate vaccine. Vaccine 2007, 25:4085-4092.
24. Ledgerwood JE, Graham BS DNA vaccines: a safe and efficient platform technology for responding to emerging infectious diseases. Hum Vaccin 2009, 5:623-626.
25. Ledgerwood JE, Pierson TC, Hubka SA, et al. A West Nile virus DNA vaccine utilizing a modified promoter induces neutralizing antibody in younger and older healthy adults in a phase I clinical trial. J Infect Dis 2011, 203:1396-1404.
26. Martin JE, Louder MK, Holman LA, et al. A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a phase I clinical trial. Vaccine 2008, 26:6338-6343.
27. Martin JE, Pierson TC, Hubka S, et al. A West Nile virus DNA vaccine induces neutralizing antibody in healthy adults during a phase 1 clinical trial. J Infect Dis 2007, 196:1732-1740.
28. Tavel JA, Martin JE, Kelly GG, et al. Safety and immunogenicity of a gag-pol candidate HIV-1 DNA vaccine administered by a needle-free device in HIV-1-seronegative subjects. J Acquir Immune Defic Syndr 2007, 44:601-605.
29. Jaoko W, Karita E, Kayitenkore K, et al. Safety and immunogenicity study of multiclade HIV-1 adenoviral vector vaccine alone or as boost following a multiclade HIV-1 DNA vaccine in Africa. PLoS One 2010, 5:e12873.
30. Kibuuka H, Kimutai R, Maboko L, et al. A phase 1/2 study of a multiclade HIV-1 DNA plasmid prime and recombinant adenovirus serotype 5 boost vaccine in HIV-uninfected east Africans (RV 172). J Infect Dis 2010, 201:600-607.
31. Sui J, Sheehan J, Hwang WC, et al. Wide prevalence of heterosubtypic broadly neutralizing human anti-influenza a antibodies. Clin Infect Dis 2011, 52:1003-1009.
32. Martin J, Pierson T, Louder M, Nabel G, Graham B DNA vaccines developed for emerging infectious diseases induce neutralizing antibody and cellular immune responses in healthy adults Jan 20-25, 2008, Keystone Symposia Viral Immunity (A5); Keystone, Colorado, Abstract 248.
33. Belshe RB, Frey SE, Graham I, et al. Safety and immunogenicity of influenza A H5 subunit vaccines: effect of vaccine schedule and antigenic variant. J Infect Dis 2011, 203:666-673.
34. Wu L, Kong WP, Nabel GJ Enhanced breadth of CD4 T-cell immunity by DNA prime and adenovirus boost immunization to human immunodeficiency virus env and gag immunogens. J Virol 2005, 79:8024-8031.
35. Suguitan AL, Cheng X, Wang W, Wang S, Jin H, Lu S Influenza H5 hemagglutinin DNA primes the antibody response elicited by the live attenuated influenza a/vietnam/1203/2004 vaccine in ferrets. PLoS One 2011, 6:e21942.
36. Wang S, Parker C, Taaffe J, Solorzano A, Garcia-Sastre A, Lu S Heterologous HA DNA vaccine prime-inactivated influenza vaccine boost is more effective than using DNA or inactivated vaccine alone in eliciting antibody responses against H1 or H3 serotype influenza viruses. Vaccine 2008, 26:3626-3633.